Log In
Or create an account ->
Imperial Library
Home
About
News
Upload
Forum
Help
Login/SignUp
Index
Cover
Contents
Title
Copyright
List of Contributors
Preface
Acknowledgements
Part I: General Issues and Infectious Syndromes
Chapter 1: Timeline of Infections After Organ Transplant
Chapter 2: Timeline of Infections After Hematopoietic Stem Cell Transplant
Chapter 3: Immune Reconstitution After Myeloablative Stem Cell Transplant
Chapter 4: Pre-transplant Infectious Disease Evaluation of the Organ Transplant Candidate
Chapter 5: Pre-transplant Infectious Disease Evaluation of the Hematopoietic Stem Cell Transplant Candidate
Chapter 6: Technical Complications after Organ Transplant and Associated Infections
6.1 Anastomoses and potential technical complications associated with either a pancreas transplant or kidney transplant a
6.2 Anastomoses and potential technical complications associated with liver transplantation
6.3 Right lobe living donor liver transplant: anastomoses and selected technical complications
Chapter 7: Evaluation and Initial Treatment of Infectious Complications Among Organ Transplant Recipients
Chapter 8: Management of Infections in Kidney Transplant Recipients a
Chapter 9: Management of Infections in Pancreas Transplant Recipients a, b
Chapter 10: Management of Infections in Liver Transplant Recipients a
Chapter 11: Management of Infections in Lung, Heart–Lung, and Heart Transplant Recipients
Chapter 12: Management of Infections in Intestinal Transplant Recipients a
Chapter 13: Antimicrobial Management of Patients with Fever and Neutropenia Following Hematopoietic Stem Cell Transplantation
13.1 Stepwise approach to empiric antimicrobial therapy in febrile neutropenia a
13.2 Agents for empiric antifungal therapy in febrile neutropenia
Part II: Specific Pathogens
Chapter 14: Cytomegalovirus
14.1 Prevention of cytomegalovirus (CMV) disease in solid organ transplant (SOT) recipients
14.2 Interpretation of pediatric CMV serology in donors and recipients < 18 months a [1]
14.3 Algorithm for pre-emptive therapy of CMV in organ transplant recipients
14.4 Treatment of CMV infection and disease in SOT recipients
14.5 Suggested algorithm for the management of ganciclovir (GCV)-resistant CMV infection and disease
Chapter 15: Epstein-Barr Virus and Post-transplant Lymphoproliferative Disorders
15.1 Prevention of Epstein-Barr virus (EBV)-related Post-transplant Lymphoproliferative Disorders (PTLDs)
15.2 Pediatric EBV serology in donors and recipients < 18 months a
15.3 Treatment of PTLD a
Chapter 16: Management of herpes simplex virus
Chapter 17: Management of Varicella Zoster Virus
Chapter 18: Prevention and Treatment of Human Herpesvirus 6, 7 and 8 Infections in Transplant Recipients
Chapter 19: BK Polyomavirus and Polyomavirus-associated Nephropathy
19.1 Screening, diagnosis and intervention for polyomavirus-associated nephropathy (PyVAN) after renal transplantation
19.2 Screening for BK virus (BKV) replication in kidney transplant recipients a
19.3 Screening for BKV replication and PyVAN in non-kidney solid organ transplant (SOT) recipients
19.4 Treatment of BKV viremia or PyVAN by modification of maintenance immunosuppression
Chapter 20: Respiratory Viruses
20.1 Prevention and treatment of respiratory viral infections after transplantation
20.2 Prevention and treatment of influenza after transplantation
Chapter 21: Human Papillomavirus
21.1 Treatment of hand or plantar (cutaneous) warts after transplantation
21.2 Treatment of external anogenital warts after transplantation
Chapter 22: Hepatitis B
22.1 Hepatitis B management in hepatitis B surface antigen (HBsAg)-positive recipients
22.2 Hepatitis B management in anti-HBc-positive, HBsAg-negative, anti-HBs-positive or -negative recipients
Chapter 23: Hepatitis C Management in Transplant Candidates and Recipients
Chapter 24: Management Algorithm for Transplantation in Patients with Human Immunodeficiency Virus
24.1 Initial pre-transplant evaluation of patients with human immunodeficiency virus (HIV)
24.2 HIV patient selection criteria for transplantation
24.3 Preferred antiretroviral drugs in HIV1 transplant candidates or recipients
24.4 Drug–drug interactions and post-transplant management in transplanted patients with HIV
Chapter 25: Management of Selected Fungal Infections After Transplantation
25.1 Management of selected fungal infections after transplantation
Chapter 26: Treatment of Nocardia Infections
Chapter 27: Tuberculosis: Treatment and Prevention
27.1 Treatment of latent Mycobacterium tuberculosis (TB) infectiona
27.2 Treatment of active Mycobacterium tuberculosis infection
Chapter 28: Treatment of Non-tuberculous Mycobacterium Infections
Chapter 29: Pneumocystis jiroveci Pneumonia: Prophylaxis and Therapy
Chapter 30: Suggested Therapy of Clostridium difficile Colitis After Transplantation
Chapter 31: Diagnosis and Treatment of Multidrug-Resistant Bacteria
Chapter 32: Management of Selected Parasitic Infections After Transplant
Part III: Donor Issues
Chapter 33: Infectious Disease Evaluation of the Potential Organ Donor
Routine screening of all donors
Optional donor testing
Additional considerations in the deceased donor
Clues to the presence of infection in the deceased organ donor
Screening of the potential living donor
Resources
Chapter 34: Infectious Disease Evaluation of the Potential Hematopoietic Stem Cell Transplant Donor
Routine screening of all donors
Optional donor testing
Comments
Resources
Chapter 35: Donor-derived Infections
35.1 Potential infections that may be transmitted from donor to recipient [1,2]
35.2 Management of specific donor scenarios
Chapter 36: Estimates of Window Period a Length for Serology and Nucleic Acid Testing
Chapter 37: Estimates of Residual Risk of HIV or HCV when using Selected Increased Risk Donor Categories a
Chapter 38: Management of Recipients of Hepatitis B Core Antibody-Positive Donor Organ
Chapter 39: Donor Tuberculosis Issues: Potential Scenarios and Management
Part IV: Prevention of Infections after Transplantation
Chapter 40: Suggested Prophylaxis Regimens in Organ Transplant Recipients
Chapter 41: Antimicrobial Prophylaxis Regimen for Allogeneic Hematopoietic Stem Cell Transplant Recipients
Chapter 42: Antimicrobial Prophylaxis Regimen for Autologous Hematopoietic Stem Cell Transplant Recipients
Chapter 43: Adult Vaccination Schedule After Solid Organ Transplant a
Chapter 44: Adult Vaccination Schedule After Allogeneic Stem Cell Transplant
Chapter 45: Immunizations After Pediatric Solid Organ Transplant and Hematopoietic Stem Cell Transplant [1–4]
Chapter 46: Recommendations for Travel-related Vaccinations and Medications for Transplant Travelers
46.1 Recommendations for travel-related vaccinations for transplant travelers
46.2 Travel-related medications, adult dosages, and duration
46.3 Interactions between transplant and travel-related medications a
Chapter 47: Safe Living Strategies for Transplant Patients
Part V: Post-transplant Medications and Drug Interactions
Chapter 48: Common Immunosuppressive Drugs, Mechanisms of Action, Side-effects, and Other Interactions
Chapter 49: Infectious Risks Associated with Anti-thymocyte Globulin (ATG, Thymoglobulin)
Chapter 50: Infectious Risks Associated with Alemtuzumab (Campath)
Chapter 51: Infectious Risks Associated with IL-2R Antagonist [Basiliximab (Simulect) and Daclizumab (Zenapax)]
Chapter 52: Infectious Risks Associated With Rituximab (Rituxan)
Chapter 53: Drug Interactions Between Antimicrobial Agents and Common Immunosuppressive Drugs Used in Transplantation
Chapter 54: Antiviral Agents for Adult Transplant Recipients
Chapter 55: Antifungal Agents in Adult Transplant Recipients
Chapter 56: Antiviral Agents for Pediatric Transplant Recipients
Chapter 57: Antifungal Agents for Pediatric Transplant Recipients
Index
← Prev
Back
Next →
← Prev
Back
Next →